永井 成勲 ながい しげのり 先生

来歴等

略歴

1995年 和歌山県立医科大学 医学部 卒業
1995年 東京都立駒込病院 外科 研修医
2000年 東京都立駒込病院 病理科 医員
2005年 東京大学大学院 医学系研究科・博士課程 修了
2005年 東京大学医科学研究所附属病院・外科医員
2007年 自治医科大学附属病院・臨床腫瘍科病院助教
2008年 埼玉県立がんセンター 乳腺腫瘍内科 医長
2011年 埼玉県立がんセンター 乳腺腫瘍内科 副部長

論文

• The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study. Breast Cancer Res Treat. 2021 Jan;185(1):125-134.

  Takahashi M, Ohtani S, Nagai SE, Takashima S, Yamaguchi M, Tsuneizumi M, Komoike Y, Osako T, Ito Y, Ikeda M, Ishida K, Nakayama T, Takashima T, Asakawa T, Matsumoto S, Shimizu D, Masuda N.

• TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study. Invest New Drugs. 2020 Feb;38(1):140-147.

  Inoue K, Nagai SE, Saito T, Sakurai T, Kimizuka K, Yamada H, Kuroda T, Hata S, Yamazaki Y, Kojima M, Futsuhara K; SBCCSG-14 investigators.

• The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition。Breast Cancer. 2020 May;27(3):322-331.

  Shimoi T, Nagai SE, Yoshinami T, Takahashi M, Arioka H, Ishihara M, Kikawa Y, Koizumi K, Kondo N, Sagara Y, Takada M, Takano T, Tsurutani J, Naito Y, Nakamura R, Hattori M, Hara F, Hayashi N, Mizuno T, Miyashita M, Yamashita N, Yamanaka T, Saji S, Iwata H, Toyama T.

• Dose-dense adjuvant chemotherapy: a systematic review and meta-analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2018 edition. Breast Cancer. 2020 May;27(3):334-339.

  Yoshinami T, Koizumi K, Nagai SE, Toyama T, Iwata H.　

• A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. Br J Cancer. 2019 Mar;120(5):475-480.

  Fujiwara Y, Mukai H, Saeki T, Ro J, Lin YC, Nagai SE, Lee KS, Watanabe J, Ohtani S, Kim SB, Kuroi K, Tsugawa K, Tokuda Y, Iwata H, Park YH, Yang Y, Nambu Y.

• BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy. Genes Chromosomes Cancer. 2017 May;56(5):405-420.

  Takada M, Nagai S, Haruta M, Sugino RP, Tozuka K, Takei H, Ohkubo F, Inoue K, Kurosumi M, Miyazaki M, Sato-Otsubo A, Sato Y, Ogawa S, Kaneko Y.

• Cross-cultural comparison of breast cancer patients' Quality of Life in the Netherlands and Japan. Breast Cancer Res Treat. 2017 Nov;166(2):459-471.

  Fischer MJ, Inoue K, Matsuda A, Kroep JR, Nagai S, Tozuka K, Momiyama M, Weijl NI, Langemeijer-Bosman D, Ramai SRS, Nortier JWR, Putter H, Yamaoka K, Kubota K, Kobayashi K, Kaptein AA.

• RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer. Clin Breast Cancer. 2017 Dec;17(8):585-594.

  Baselga J, Zamagni C, G?mez P, Bermejo B, Nagai SE, Melichar B, Chan A, M?ngel L, Bergh J, Costa F, G?mez HL, Gradishar WJ, Hudis CA, Rapoport BL, Roch? H, Maeda P, Huang L, Meinhardt G, Zhang J, Schwartzberg LS.

• A Real-World Retrospective Cohort Study of Combined Therapy with Bevacizumab and Paclitaxel in Japanese Patients with Metastatic Breast Cancer. J Nippon Med Sch. 2017;84(5):215-223.

  Yamada H, Inoue K, Nagai SE, Nakai M, Arisawa F, Ueda H, Saito T, Ninomiya J, Kuroda T, Sakurai T, Kodama H, Kimizuka K, Hata S, Kai T, Kurosumi M; SBCCSG investigators.

• Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2015 edition。Breast Cancer. 2016 23:329-342.

  Aihara T, Toyama T, Takahashi M, Yamamoto Y, Hara F, Akabane H, Fujisawa T, Ishikawa T, Nagai S, Nakamura R, Tsurutani J, Ito Y, Mukai H.

• Impact of immediate breast reconstruction on postoperative adjuvant chemotherapy: a single center study. Breast Cancer. 2015 May;22(3):287-91.

  Hamahata A, Kubo K, Takei H, Saitou T, Hayashi Y, Matsumoto H, Nagai S, Inoue K, Kurosumi M, Yamaki T, Sakurai H.

• Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study). Breast Cancer Res Treat. 2014 May;145(1):143-53.

  Takada M, Ishiguro H, Nagai S, Ohtani S, Kawabata H, Yanagita Y, Hozumi Y, Shimizu C, Takao S, Sato N, Kosaka Y, Sagara Y, Iwata H, Ohno S, Kuroi K, Masuda N, Yamashiro H, Sugimoto M, Kondo M, Naito Y, Sasano H, Inamoto T, Morita S, Toi M.

• Analysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancer. Oncol Lett. 2013 Jan;5(1):83-89.

  Hayashi Y, Takei H, Nozu S, Tochigi Y, Ichikawa A, Kobayashi N, Kurosumi M, Inoue K, Yoshida T, Nagai SE, Oba H, Tabei T, Horiguchi J, Takeyoshi I.

• Sentinel lymph node biopsy after neoadjuvant chemotherapy predicts pathological axillary lymph node status in breast cancer patients with clinically positive axillary lymph nodes at presentation. Int J Clin Oncol. 2013 Jun;18(3):547-53.

  Takei H, Yoshida T, Kurosumi M, Inoue K, Matsumoto H, Hayashi Y, Higuchi T, Uchida S, Ninomiya J, Kubo K, Oba H, Nagai S, Tabei T.

• Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages? Breast Cancer. 2011 Apr;18(2):85-91.

  Takei H, Kurosumi M, Yoshida T, Hayashi Y, Higuchi T, Uchida S, Ninomiya J, Oba H, Inoue K, Nagai S, Tabei T.

• Axillary lymph node dissection can be avoided in women with breast cancer with intraoperative, false-negative sentinel lymph node biopsies. Breast Cancer. 2010;17(1):9-16.

  Takei H, Kurosumi M, Yoshida T, Ishikawa Y, Hayashi Y, Ninomiya J, Tozuka K, Oba H, Inoue K, Nagai S, Saito Y, Kazumoto T, Saitoh J, Tabei T.